Dan Rathbone

Personal profile

General

I became a lecturer in pharmaceutical sciences in the Aston School of Pharmacy in 1999. Prior to that I had undertaken postdoctoral research in synthetic chemistry at Bonn and Aston as well as nearly six years working for a contract research company. My research interests have broadened out from synthetic chemistry to include molecular modelling and drug design. The current focus is on the design and synthesis of antimicrobial compounds, tissue transglutaminase inhibitors and the application of computational methods to pharmaceutical formulations.

Research Interests

Design, synthesis and screening of libraries of new antimycobacterial compounds
Computer aided drug design
Molecular recognition in fluorescent imprinted polymers and their use as sensors and receptor mimics
Design and synthesis of transglutaminase inhibitors

Teaching Activity

Aston Pharmacy School MPharm course: Chemical aspects of pharmacy.

Various MSc courses: Drug design and drug discovery.

Undergraduate biology and biochemistry courses: Chemistry for biology

Qualifications

PhD (Chemistry, Warwick University, 1987)

BA (Chemistry, St Edmund Hall, Oxford University)

Contact Details

Telephone: +44 (0) 121 204 4002

Room: MB357D

Email: D.L.Rathbone@aston.ac.uk

Keywords

QD Chemistry
Molecular modelling
Drug design
Antimicrobial compounds
Transglutaminase inhibitors
Chemical synthesis

Fingerprint Dive into the research topics where Dan Rathbone is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

3 Similar Profiles

Mononuclear Leukocytes Medicine & Life Sciences

Polymers Medicine & Life Sciences

acetolactate decarboxylase Medicine & Life Sciences

Toxicity Chemical Compounds

Toxicology Medicine & Life Sciences

Derivatives Chemical Compounds

Poisons Medicine & Life Sciences

Tuberculosis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2000 2019

30 Article
1 Meeting abstract
1 Patent

Design, Stability and Efficacy of a New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells

Huey, R., Rathbone, D., McCarron, P. & Hawthorne, S., 21 Oct 2019, In : Journal of Drug Targeting. 27, 9, p. 959-970 12 p.

Research output: Contribution to journal › Article

amsonic acid

Neuroblastoma

Peptides

Rabies virus

Nanoparticles

Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors

Jasim, M. & Rathbone, D. L., 1 Jan 2018, In : Journal of Molecular Graphics and Modelling . 79, p. 157-165 9 p.

Research output: Contribution to journal › Article

Open Access

File

Neurodegenerative diseases

Acrylamide

Protonation

Michael reaction

Crosslinking

Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions

Badarau, E., Wang, Z., Rathbone, D. L., Costanzi, A., Thibault, T., Murdoch, C. E., El Alaoui, S., Bartkeviciute, M. & Griffin, M., 22 Oct 2015, In : Chemistry and Biology. 22, 10, p. 1347-1361 15 p.

Research output: Contribution to journal › Article

Open Access

File

Endothelial cells

Fibronectins

Syndecan-4

Umbilical Cord

Peptidomimetics

TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles

Griffin, M., Wang, Z., Thibault, T., Murdoch, C. & Rathbone, D., 31 Aug 2015, In : Amino Acids. 47, 8, p. 1629 1 p.

Research output: Contribution to journal › Meeting abstract

Fibrosis

Collagen

Fibronectins

Proteins

Chemical activation

Compound for treating clostridium difficile

Rathbone, D. L., Worthington, A., Al-Malaika, S., Hird, M. & Quayle, A., 2014, Patent No. US20170320906A1, Priority date 27 Nov 2014

Research output: Patent

Open Access